Biologics CDMO Market Trends
Growing number of cancer cases to support market expansion
One of the main drivers of the biologics CDMO market's expansion is the increasing incidence of cancer disorders. Because of poor and unhealthy lifestyle choices, there is an increase in various types of cancer. There is an increase in pancreatic cancer, liver and kidney cancer, lung cancer, breast cancer, and lung cancer. Cancer treatments are now the primary factor propelling the biologics CDMO market's expansion. For example, the Centers for Disease Control and Prevention (CDC) reports that there were 1,752,735 new cancer cases reported in the US in 2019 and 599,589 cancer-related deaths. There were 146 cancer-related deaths and 439 newly reported cases of the disease for every 100,000 individuals.
Growing demand from up-and-coming biotech and pharmaceutical firms for CDMOs
The target market is growing because pharmaceutical and biotech companies demand more CDMOs. The expansion of the target market is now significantly influenced by the increase in clinical trials. The Food and Drug Administration (FDA) reports that major and emerging biotech or pharmaceutical companies are currently conducting about 50 cell and gene therapy clinical trials. Additional benefits of outsourcing include lower investment risks, specialized knowledge, cutting-edge tools and technology, higher productivity and efficiency, less labor work, and suitability for startups and small businesses. One of the biopharmaceutical industry's fastest-growing segments is CAGT (Cell & Gene Therapy), which results from growing demand for innovative biologics.
As an example, Samsung Biologics, a fully integrated CDMO, obtained over 50 drug approvals following 30 inspections by regulatory bodies. The company uses cutting-edge technologies to meet the demands of the biopharmaceutical industries by offering high-quality lab testing and manufacturing services. As of 2017, the company operated three manufacturing facilities, housing approximately 364,000 liters of mammalian cell culture, the largest capacity for producing antibodies.
Limitations:
Cost pressure, intense competition, consolidation, and ongoing technological advancements that could impede market growth are some of the difficulties faced by CDMOs. Choosing the correct cutting-edge CDMO solution provider can result in a positive customer experience, and differences in customer service standards can cause issues with quality. Additionally, it might result in less control over the production process, which would be a disadvantage and challenge for CDMOs, hindering the growth of the biologics CDMO market.